Elanco’s Zenrelia™ Study Shows Promising Results in Dogs

Elanco Animal Health ( (ELAN) ) has shared an update.

Elanco Animal Health presented findings at an ISCAID symposium showing that their novel JAK inhibitor, Zenrelia™, didn’t alter serologic responses in dogs after booster vaccinations. The study, involving young Beagle dogs, found no significant differences in protective titers between treated and control groups, with no serious adverse events. Zenrelia™ has also gained approval in Canada.

For a thorough assessment of ELAN stock, go to TipRanks’ Stock Analysis page.